← Back to Search

Immunostimulant

ALT-803 for Multiple Myeloma

Phase 1
Waitlist Available
Research Sponsored by Altor BioScience
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 years
Awards & highlights

Study Summary

This is a Phase I/II, open-label, multi-center, competitive enrollment and dose escalation study of ALT-803 in patients with relapsed or refractory multiple myeloma.

Eligible Conditions
  • Multiple Myeloma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
MTD or MED Determination, Phase II Dose Level Designation
Safety Profile
Secondary outcome measures
Biomarkers
Blood Cell Counts
Clinical Benefit
+3 more

Side effects data

From 2019 Phase 2 trial • 8 Patients • NCT03050216
88%
Chills
88%
Injection site reaction
75%
Headache
63%
Fever
63%
Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other
50%
Fatigue
50%
Febrile neutropenia
50%
Hypertension
50%
Hypotension
38%
Infusion related reaction
25%
Dizziness
25%
Hypoxia
25%
Pain
25%
Skin and subcutaneous tissue disorders - Other
13%
Rash maculo-papular
13%
Adult respiratory distress syndrome
13%
Anxiety
13%
Dyspnea
13%
Gastroesophageal reflux disease
13%
Diarrhea
13%
Nervous system disorders - Other
13%
Oral pain
13%
Myalgia
13%
Cough
13%
Hypophosphatemia
13%
Generalized muscle weakness
13%
Vomiting
13%
Aspartate aminotransferase increased
13%
Sepsis
13%
Clostridium Difficile Infection
13%
Alanine aminotransferase increased
13%
Febrile neutropenia - Changed to levaquin and micafungin
13%
Heart failure
13%
Lung infection
13%
Tumor lysis syndrome
13%
Acute kidney injury
13%
Disseminated intravascular coagulation
13%
Atrial fibrillation
13%
Constipation
13%
Blood bilirubin increased
13%
Urine output decreased
13%
Anorexia
13%
Hypoalbuminemia
13%
Hypocalcemia
100%
80%
60%
40%
20%
0%
Study treatment Arm
Cy, FLU, Haplo NK and ALT-803

Trial Design

1Treatment groups
Experimental Treatment
Group I: ALT-803Experimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Inbakicept
Not yet FDA approved

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,680 Previous Clinical Trials
40,928,566 Total Patients Enrolled
584 Trials studying Multiple Myeloma
189,302 Patients Enrolled for Multiple Myeloma
Altor BioScienceLead Sponsor
17 Previous Clinical Trials
578 Total Patients Enrolled
2 Trials studying Multiple Myeloma
6 Patients Enrolled for Multiple Myeloma
Hing C Wong, PhDStudy ChairAltor BioScience
5 Previous Clinical Trials
298 Total Patients Enrolled
1 Trials studying Multiple Myeloma
6 Patients Enrolled for Multiple Myeloma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
QUILT-3.005: A Study of ALT-803 in Patients With Relapsed or Refractory Multiple Myeloma
2014. "QUILT-3.005: A Study of ALT-803 in Patients With Relapsed or Refractory Multiple Myeloma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02099539.
All > Myeloma
~2 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top